Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

208.80 USD +5.90 (+2.91%)
Streaming Delayed Price Updated: 2:59 PM EST, Jan 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 287,914
Open 202.06
Bid (Size) 208.69 (3)
Ask (Size) 209.68 (2)
Prev. Close 202.90
Today's Range 194.50 - 209.71
52wk Range 200.75 - 426.56
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation
BeiGene announces an sNDA for BRUKINSA in first-line chronic lymphocytic leukemia has been accepted in China with breakthrough therapy designation. 
From Business Wire News Releases

Performance

YTD
-22.54%
-22.54%
1 Month
-22.86%
-22.86%
3 Month
-42.73%
-42.73%
6 Month
-33.12%
-33.12%
1 Year
-34.89%
-34.89%

More News

Read More
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
From Business Wire News Releases
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
From Business Wire News Releases
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
Tags Earnings NRIX RMD
From Benzinga
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
From Business Wire News Releases
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
From Business Wire News Releases
Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies
Tags IMMX Preclinical Phase Benzinga
From Benzinga
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
Tags News Market News NVAX
From Benzinga
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
From Business Wire News Releases
Leap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients
Tags Trading Ideas News Market News
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.